Biopharmaceutical Company Announces Second Quarter 2024 Financial Results

ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company specializing in manufacturing and marketing specialty biologics, has announced its financial results for the second quarter of 2024. The company reported growth in revenue, net income, and adjusted EBITDA, reflecting the robustness of its operations and initiatives. $ADMA Biologics (ADMA.US)$